These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35164737)

  • 1. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder.
    Doane MJ; Bessonova L; Friedler HS; Mortimer KM; Cheng H; Brecht T; O'Sullivan AK; Cummings H; McDonnell D; Meyer JM
    BMC Psychiatry; 2022 Feb; 22(1):114. PubMed ID: 35164737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
    Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN
    J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups.
    Doane MJ; Raymond K; Saucier C; Bessonova L; O'Sullivan AK; White MK; Foster AM; LaGasse K; Carpenter-Conlin J; Sajatovic M; Velligan DI
    BMC Psychiatry; 2023 Apr; 23(1):245. PubMed ID: 37046256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients.
    Wang PW; Hill SJ; Childers ME; Chandler RA; Rasgon NL; Ketter TA
    J Psychiatr Res; 2011 Aug; 45(8):1128-32. PubMed ID: 21371718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders.
    Ayyagari R; Thomason D; Mu F; Philbin M; Carroll B
    J Med Econ; 2020 Feb; 23(2):204-212. PubMed ID: 31663802
    [No Abstract]   [Full Text] [Related]  

  • 9. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
    McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE
    Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment.
    Khandker R; Chekani F; Limone B; Thiel E
    BMC Psychiatry; 2022 Feb; 22(1):133. PubMed ID: 35183142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.
    Treuer T; Hoffmann VP; Chen AK; Irimia V; Ocampo M; Wang G; Singh P; Holt S
    World J Biol Psychiatry; 2009; 10(4 Pt 3):729-40. PubMed ID: 19606406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
    Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
    BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review.
    Doane MJ; Ogden K; Bessonova L; O'Sullivan AK; Tohen M
    Neuropsychiatr Dis Treat; 2021; 17():515-531. PubMed ID: 33623386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.
    Marteene W; Winckel K; Hollingworth S; Kisely S; Gallagher E; Hahn M; Ebdrup BH; Firth J; Siskind D
    Expert Opin Drug Saf; 2019 Dec; 18(12):1149-1160. PubMed ID: 31564170
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology.
    Rojo LE; Gaspar PA; Silva H; Risco L; Arena P; Cubillos-Robles K; Jara B
    Pharmacol Res; 2015 Nov; 101():74-85. PubMed ID: 26218604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.